DNMT3A mutations define a unique biological and prognostic subgroup associated with cytotoxic T cells in PTCL-NOS.
Journal
Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509
Informations de publication
Date de publication:
15 09 2022
15 09 2022
Historique:
received:
01
12
2021
accepted:
08
04
2022
pubmed:
1
6
2022
medline:
20
9
2022
entrez:
31
5
2022
Statut:
ppublish
Résumé
Peripheral T-cell lymphomas (PTCLs) are heterogenous T-cell neoplasms often associated with epigenetic dysregulation. We investigated de novo DNA methyltransferase 3A (DNMT3A) mutations in common PTCL entities, including angioimmunoblastic T-cell lymphoma and novel molecular subtypes identified within PTCL-not otherwise specified (PTCL-NOS) designated as PTCL-GATA3 and PTCL-TBX21. DNMT3A-mutated PTCL-TBX21 cases showed inferior overall survival (OS), with DNMT3A-mutated residues skewed toward the methyltransferase domain and dimerization motif (S881-R887). Transcriptional profiling demonstrated significant enrichment of activated CD8+ T-cell cytotoxic gene signatures in the DNMT3A-mutant PTCL-TBX21 cases, which was further validated using immunohistochemistry. Genomewide methylation analysis of DNMT3A-mutant vs wild-type (WT) PTCL-TBX21 cases demonstrated hypomethylation in target genes regulating interferon-γ (IFN-γ), T-cell receptor signaling, and EOMES (eomesodermin), a master transcriptional regulator of cytotoxic effector cells. Similar findings were observed in a murine model of PTCL with Dnmt3a loss (in vivo) and further validated in vitro by ectopic expression of DNMT3A mutants (DNMT3A-R882, -Q886, and -V716, vs WT) in CD8+ T-cell line, resulting in T-cell activation and EOMES upregulation. Furthermore, stable, ectopic expression of the DNMT3A mutants in primary CD3+ T-cell cultures resulted in the preferential outgrowth of CD8+ T cells with DNMT3AR882H mutation. Single-cell RNA sequencing(RNA-seq) analysis of CD3+ T cells revealed differential CD8+ T-cell subset polarization, mirroring findings in DNMT3A-mutated PTCL-TBX21 and validating the cytotoxic and T-cell memory transcriptional programs associated with the DNMT3AR882H mutation. Our findings indicate that DNMT3A mutations define a cytotoxic subset in PTCL-TBX21 with prognostic significance and thus may further refine pathological heterogeneity in PTCL-NOS and suggest alternative treatment strategies for this subset.
Identifiants
pubmed: 35639959
pii: S0006-4971(22)00713-3
doi: 10.1182/blood.2021015019
pmc: PMC9479030
doi:
Substances chimiques
Receptors, Antigen, T-Cell
0
Interferon-gamma
82115-62-6
Methyltransferases
EC 2.1.1.-
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1278-1290Subventions
Organisme : NCI NIH HHS
ID : T32 CA009476
Pays : United States
Références
Int J Hematol. 2011 Feb;93(2):176-185
pubmed: 21229399
J Biol Chem. 2012 Sep 7;287(37):30941-51
pubmed: 22722925
Blood. 2014 Feb 27;123(9):1293-6
pubmed: 24345752
Nat Genet. 2014 Feb;46(2):171-5
pubmed: 24413737
Nat Rev Cancer. 2015 Mar;15(3):152-65
pubmed: 25693834
Blood. 2013 Jun 6;121(23):4769-77
pubmed: 23632886
Clin Cancer Res. 2021 Nov 1;27(21):6039-6053
pubmed: 34426436
Blood Adv. 2021 Jan 26;5(2):539-548
pubmed: 33496747
Cancer Cell. 2014 Apr 14;25(4):442-54
pubmed: 24656771
Cancer Res. 2019 Jul 15;79(14):3583-3594
pubmed: 31164355
Cancer Cell. 2018 Feb 12;33(2):259-273.e7
pubmed: 29398449
Nat Immunol. 2019 Feb;20(2):163-172
pubmed: 30643263
Sci Rep. 2016 Sep 28;6:34222
pubmed: 27677595
Blood. 2010 Feb 4;115(5):1026-36
pubmed: 19965671
J Biol Chem. 2012 Jun 29;287(27):22900-9
pubmed: 22584578
Proc Natl Acad Sci U S A. 2017 Jan 24;114(4):764-769
pubmed: 28062691
Genes Chromosomes Cancer. 2013 Apr;52(4):410-22
pubmed: 23341344
J Clin Invest. 2012 Oct;122(10):3448-55
pubmed: 23023716
Cancer Cell. 2016 Jul 11;30(1):92-107
pubmed: 27344947
Expert Rev Hematol. 2019 Nov;12(11):927-935
pubmed: 31487202
Proc Natl Acad Sci U S A. 2016 Sep 20;113(38):10631-6
pubmed: 27582468
J Hematol Oncol. 2017 Apr 14;10(1):85
pubmed: 28410601
Nat Commun. 2019 May 1;10(1):2011
pubmed: 31043609
Haematologica. 2017 Apr;102(4):e148-e151
pubmed: 28082343
Blood. 2018 Aug 30;132(9):935-947
pubmed: 29769264
Oncotarget. 2017 Oct 27;8(63):106948-106961
pubmed: 29291002
Nat Immunol. 2020 May;21(5):492-494
pubmed: 32231299
Leukemia. 2011 Feb;25(2):348-58
pubmed: 21052088
Leukemia. 2012 May;26(5):1106-7
pubmed: 22124213
Blood. 2015 Oct 8;126(15):1741-52
pubmed: 26268241
N Engl J Med. 2010 Dec 16;363(25):2424-33
pubmed: 21067377
Oncogene. 2006 Mar 9;25(10):1560-70
pubmed: 16288225
Cancer Sci. 2018 Mar;109(3):490-496
pubmed: 28889481
J Clin Oncol. 2011 Jul 20;29(21):2889-96
pubmed: 21670448
Nat Genet. 2014 Feb;46(2):166-70
pubmed: 24413734
Cancer. 2017 Apr 1;123(7):1174-1183
pubmed: 27911989
Cold Spring Harb Perspect Med. 2017 Feb 1;7(2):
pubmed: 28003281
N Engl J Med. 2012 Jan 5;366(1):95-6
pubmed: 22216861
EMBO J. 2006 Jun 7;25(11):2443-52
pubmed: 16724115
Nature. 2010 Dec 9;468(7325):839-43
pubmed: 21057493
Int J Hematol. 2014 Mar;99(3):219-26
pubmed: 24481943
Proc Natl Acad Sci U S A. 2017 May 16;114(20):5237-5242
pubmed: 28461508
J Clin Exp Hematop. 2017;57(3):109-119
pubmed: 29279549
Am J Hematol. 2019 Jun;94(6):628-634
pubmed: 30829413
Leukemia. 2016 May;30(5):1062-70
pubmed: 26719098
Nature. 2018 Feb 15;554(7692):387-391
pubmed: 29414941
Blood. 2014 May 8;123(19):2915-23
pubmed: 24632715
Nature. 2019 Sep;573(7773):281-286
pubmed: 31485078
Blood. 2007 Jun 1;109(11):4952-63
pubmed: 17284527
Cancer Treat Res. 2019;176:31-68
pubmed: 30596212
PLoS Genet. 2016 Sep 30;12(9):e1006334
pubmed: 27690235
Blood. 2019 Apr 11;133(15):1664-1676
pubmed: 30782609
Haematologica. 2016 Nov;101(11):e457-e460
pubmed: 27418649
Nat Commun. 2020 Jun 24;11(1):3199
pubmed: 32581223
Methods Mol Biol. 2018;1711:243-259
pubmed: 29344893
Nat Med. 2018 Jan;24(1):103-112
pubmed: 29227476
J Clin Pathol. 2008 Nov;61(11):1160-7
pubmed: 18755717
Oncogenesis. 2020 Feb 3;9(2):7
pubmed: 32015320
Blood Rev. 2016 Mar;30(2):89-100
pubmed: 26319391
Oncotarget. 2016 Oct 4;7(40):65284-65294
pubmed: 27589565
Cell Rep. 2018 Apr 3;23(1):1-10
pubmed: 29617651
Blood. 2014 May 8;123(19):3007-15
pubmed: 24497534
Hematol Oncol Clin North Am. 2008 Oct;22(5):997-1005, x
pubmed: 18954748
Blood. 2013 Jun 20;121(25):4997-5005
pubmed: 23652805
Genome Biol. 2018 Dec 19;19(1):224
pubmed: 30567574
J Immunol. 2013 Jul 15;191(2):902-11
pubmed: 23772023
Blood. 2014 Mar 27;123(13):2034-43
pubmed: 24497536
J Clin Oncol. 2012 Mar 1;30(7):742-50
pubmed: 22291079
Nature. 2017 Dec 21;552(7685):404-409
pubmed: 29236683
J Mol Biol. 2019 Dec 6;431(24):5063-5074
pubmed: 31634469
Nucleic Acids Res. 2019 Dec 2;47(21):11355-11367
pubmed: 31620784
J Clin Invest. 2007 Mar;117(3):823-34
pubmed: 17304354
Bioinformatics. 2007 Dec 1;23(23):3251-3
pubmed: 17644558
Haematologica. 2017 Sep;102(9):e356-e359
pubmed: 28659334
Methods Mol Biol. 2020;2120:263-276
pubmed: 32124326
Blood. 2016 Sep 15;128(11):1490-502
pubmed: 27369867
Leukemia. 2019 Dec;33(12):2867-2883
pubmed: 31092896
Blood. 2019 Dec 12;134(24):2159-2170
pubmed: 31562134
Leukemia. 2008 Oct;22(10):1891-8
pubmed: 18633432
Clin Lymphoma Myeloma Leuk. 2017 Apr;17(4):193-200
pubmed: 28209473
Nucleic Acids Res. 2010 Jul;38(13):4246-53
pubmed: 20223770
Int J Hematol. 2016 Jun;103(6):617-26
pubmed: 26943352
Haematologica. 2019 Aug;104(8):1617-1625
pubmed: 30655366